AREDS2 Explained: What the Study Did and Didn't Show

Why this article exists

"AREDS2" appears on a lot of supplement bottles, often with implications the research never supported. This guide explains what the AREDS and AREDS2 trials actually studied, what their formula contains, and — just as importantly — the boundaries of the evidence. Nothing here is medical advice; supplement decisions belong with your eye-care professional.

What AREDS and AREDS2 were

The Age-Related Eye Disease Study (AREDS), run by the U.S. National Eye Institute, tested whether a specific high-dose antioxidant and zinc formula could slow the progression of age-related macular degeneration (AMD). The follow-up trial, AREDS2 (JAMA, 2013), refined that formula — removing beta-carotene (linked to higher lung-cancer risk in smokers) and adding the carotenoids lutein and zeaxanthin ¹.

The AREDS2 formula contains:

• Vitamin C 500 mg
• Vitamin E 400 IU
• Zinc 80 mg (or a lower-zinc variant studied)
• Copper 2 mg
• Lutein 10 mg + Zeaxanthin 2 mg

What the studies did show

In people who already had intermediate AMD, or advanced AMD in one eye, the AREDS/AREDS2 formula reduced the risk of progression to advanced AMD by a modest amount over five years ¹². That is a meaningful, evidence-based finding for that specific group, and it is why eye doctors may recommend the formula to those patients.

What the studies did not show (the important limits)

This is where most marketing overreaches. Read carefully:

• AREDS2 was not a prevention study for healthy eyes. It enrolled people who already had AMD or were at high risk. It did not show that the supplement prevents AMD in people with healthy eyes or no risk factors ².
• It did not show benefit for early AMD — only intermediate-to-late disease.
• It is not a treatment that reverses or cures AMD; at best it slows progression in the studied group.
• High-dose zinc and antioxidant formulas are not risk-free and can interact with other conditions and medications — another reason the decision is a clinical one ².

In plain terms: a bottle that says "AREDS2 formula" is selling a specific vitamin recipe. Whether you should take it depends entirely on whether your eyes match the population the trial studied — a question for your ophthalmologist, not a label.

Language we avoid

Because this is a health topic, we are deliberate about wording:

• We never say a supplement "prevents macular degeneration." The accurate statement is that AREDS2 slowed progression to advanced AMD in people who already had intermediate or advanced disease.
• We never describe AREDS2 as "recommended for healthy eyes." It was not designed for, or tested in, low-risk eyes.
• We cite the primary trial rather than vague phrases like "studies show."

What to do with this information

1. If you have been told you have intermediate or advanced AMD, ask your eye-care professional whether the AREDS2 formula is appropriate for you specifically.
2. If your eyes are healthy or you only have early changes, there is no evidence that the formula helps — discuss diet, smoking cessation, and monitoring instead.
3. Treat any product implying the supplement prevents or cures AMD as a marketing claim the research does not support.

When to seek care

AMD and other macular problems can change suddenly. New distortion of straight lines, a dark or blank spot in central vision, or a rapid drop in vision are reasons to contact an ophthalmologist promptly rather than to start a supplement. See the medical disclaimer for emergency guidance. Regular dilated eye exams remain the cornerstone of catching AMD early ³.

References